A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Age-related macular degeneration (AMD ... we haven’t had any therapeutics to target the root cause of geographic atrophy, an advanced form of dry AMD. Pegcetacoplan (Syfovre) is the first ...

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

today announced positive topline 3-month data from a clinical trial of its K8 implant in patients with geographic atrophy (GA), the most serious form of dry age-related macular degeneration (AMD).

About SYFOVRE® (pegcetacoplan injection) SYFOVRE ® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide ...

for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an intact fovea and when central vision is threatened by ...